ACTINIUM PHARMACEUTICALS, INC. (NYSEMKT:ATNM) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07.Submission of Matters to a Vote of Security Holders.
On December21, 2016, Actinium Pharmaceuticals, Inc. (Actinium)
held its 2016 Annual Meeting of Stockholders (the Annual
Meeting). Of the 55,747,108 shares of the Companys common stock
outstanding and eligible to vote at the Annual Meeting,
29,334,121 shares, or approximately 52.6% of the eligible common
stock, were present either in person or by proxy.All matters
submitted to a vote of the Companys stockholders at the Annual
Meeting were approved and the director nominee was elected. The
final results of the matters voted on at the Annual Meeting are
provided below.
Proposal 1: The following individual was elected as a
director to hold office for the term described below or until his
resignation, or respective successor is elected and qualified:
| Director Name | For | Against | Abstain | Broker Non-Votes | ||||||||||||
| Kaushik J. Dave (Class III, 36 month term) | 9,472,599 | 3,156,465 | 376,893 | 16,062,482 | ||||||||||||
Proposal 2: GBH CPAs, PC was ratified as the Companys
Independent Registered Public Accounting Firm for the fiscal year
ending December 31, 2017.
| For: | 26,835,760 | |||
| Against: | 1,808,733 | |||
| Abstained: | 423,946 |
Proposal 3: An amendment to the Companys 2013 Amended and
Restated Stock Plan to increase the number of shares authorized
to issue under the plan by 3.5 million shares was approved.
| For: | 8,082,170 | |||
| Against: | 4,233,093 | |||
| Abstained: | 690,694 | |||
| Broker Non-Votes: | 16,062,482 |
Proposal 4: A non-binding vote on 2015 executive
compensation was approved.
| For: | 8,772,044 | |||
| Against: | 3,943,740 | |||
| Abstained: | 340,173 | |||
| Broker Non-Votes: | 16,062,482 |
About ACTINIUM PHARMACEUTICALS, INC. (NYSEMKT:ATNM)
Actinium Pharmaceuticals, Inc. (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131). Actimab-A is in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. Its products under development are monoclonal antibodies labeled with radioisotopes. It has four product candidates in clinical trials: Actimab-A (HuM195-Ac-225), Iomab-B (BC8-I-131), BC8-Y-90 and BC8-SA. It is pursuing development of Actimab-A and Iomab-B, while BC8-Y-90 and BC8-SA are in physician sponsored clinical phase I trials. ACTINIUM PHARMACEUTICALS, INC. (NYSEMKT:ATNM) Recent Trading Information
ACTINIUM PHARMACEUTICALS, INC. (NYSEMKT:ATNM) closed its last trading session up +0.020 at 0.980 with 289,908 shares trading hands.
